Photocure to Present New Data on Cysview® at the 2018 American Urological Association Annual Meeting

Published: 14 May 2018

Oslo, Norway, May 14th, 2018: Photocure ASA (PHO:OSE) announced today that Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in Booth 1825, during the American Urological Association Meeting (AUA 2018) in San Francisco, CA.

New data on Cysview will be presented (see details below): in at least three posters, of which two are on registry studies using real world longitudinal data, a plenary session on Patient Reported Outcomes and during the Bladder Cancer Surgical Technique session Dr. James McKiernan will present on "Enhanced Cystoscopy: BLC – TURBT + Surveillance Video". Earlier this year BLC with Cysview was approved by the FDA for use in surveillance cystoscopy (in addition to the already existing approval for TURBT's (Trans Urethral Resection of the Bladder)). "I have been using BLC with Cysview for both TURBT's and surveillance. I am looking forward to sharing my experience. Using these new techniques more broadly should result in improved patient outcomes," said Dr. James McKiernan, John K Lattimer Professor and Chairman of Urology at Columbia University and Urologist-in-Chief New York Presbyterian Hospital New York.

Photocure is also unveiling the company's strategic focus, exhibiting as The Bladder Cancer Company. "In this, the Bladder Cancer Awareness month, we are excited to announce our continued focus on bladder cancer and look forward to working with the bladder cancer community to increase awareness of Bladder Cancer and our breakthrough technology, BLC with Cysview," says Kjetil Hestdal, MD, PhD, President and CEO, Photocure ASA.

Key Activities featuring Cysview during the meeting include:

  • May 18, 2018 (FRIDAY) 9:30 AM to 11:30AM – Location: MCC WEST, 3006

Blue Light Cystoscopy Improves Detection Rates: Updated Results From A Prospective Multicenter RegistryHow is outpatient blue light cystoscopy used in clinical routine? First results from the Nordic registryThe impact of Blue Light Cystoscopy on response of induction BCG in patients with high-grade non-muscle invasive bladder cancer

  • May 19, 2018 (SATURDAY) – 4:33 PM to 4:42 PM – Location: MCC South, 208

Assessment of Blue Light Flexible Cystoscopy with Cysview on Patient Reported Outcomes– by Dr. Angela Smith, University of North Carolina

  • May 20, 2018 (SUNDAY) 7:00 AM to 9:00AM – Location: MCC WEST, 2005

Blue light in combination with Cysview Leads to Bladder Cancer Cell Death in an in vitro Mode

  • 2:00 PM to 2:45 PM - MCC SOUTH, Esplanade (Plenary Session)

· Surgical Techniques: Tips & Tricks: Bladder Cancer: Moderator: Dr. Kristen Scarpato – Vanderbilt University with other Panel Members: Dr. Joe Liao – VA Palo Alto and Dr. Bernie Bochner including: Dr. James McKiernan, New York Presbyterian, Columbia University, who will present on Enhanced Cystoscopy – BLC – TURBT + Surveillance Video plus moderated presentation

  • May 17 and 18 (THURSDAY and FRIDAY), Photocure will be exhibiting at the AUA Office Practice Management Conference – Location: MCC North, 22

About Bladder Cancer

Bladder cancer is the fifth most commonly diagnosed cancer in the US and is the fourth most common cancer found in men in the US(1, 2, 3). In 2018, it is estimated that there will be 81,190 new cases of bladder cancer will occur along with 17,240 deaths due to bladder cancer. Risk factors for bladder cancer include advancing age, cigarette smoking, occupational exposure to dyes, tar, rubber and solvent, chronic bladder irritation and infections, and prior diagnosis of bladder cancer. Bladder cancer is one of the most expensive cancers to manage, accounting for approximately $3.7 billion in direct costs each year.(4,5)

Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall.2 NMIBC is still in the inner layer of cells. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.(2)

About Hexvix®/Cysview®

Hexvix®/Cysview® (hexaminolevulinate hydrochloride) is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCTM with Hexvix® /Cysview® improves the detection of tumors and leads to more complete resection, less residual tumors and better management decisions.

Hexvix® is the tradename in Europe, Cysview® in US and Canada. Hexvix® is marketed and sold by Photocure in the Nordic countries and in the US with the trade name Cysview®. Photocure has a strategic partnership with Ipsen for the commercialization of Hexvix in Europe, excluding the Nordic region. Please refer to for further information on our commercial partners.

About Photocure ASA

Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in Princeton, New Jersey. For more information, please visit us at, or

For more information, please contact:

Company contacts:

Kjetil Hestdal,
President and CEO
Tel: +47 913 19 535

Erik Dahl,
Chief Financial Officer
Tel: +47 450 55 000

Media Relations:
Amanda Hudson,
MCS Healthcare Public Relations
Tel: +1 908 234 9900


  1. SEER Cancer Statistics Factsheets: Bladder Cancer. National Cancer Institute. Bethesda, MD. Accessed April 2018.
  2. Bladder Cancer. American Cancer Society. Accessed April 2018.
  3. Hall M, Chang S, Dalbagni G et al. Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update. J Urol. 2007;178 (6):2314-2330.
  4. Avritscher EB et al., Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006; 68:549-553.
  5. Botteman et al. Clinical model of lifetime costs of treating bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003; 21:315-1330.

News and events